Safety and Immunogenicity of Recombinant Protein RBD Fusion Dimer Vaccine Against the Virus That Cause COVID-19, Known as Severe Acute Respiratoy Syndrome Coronavirus 2 (SARS-CoV-2)
Clinical trial NCT05142514 · COMPLETED
Trial details
- NCT number
- NCT05142514
- Sponsor
- Hipra Scientific, S.L.U
- Status
- COMPLETED
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2021-11-11
- Primary completion
- 2021-12-27
- Enrollment
- 629
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.